Talaris Therapeutics Ownership

TALSDelisted Stock  USD 2.98  0.10  3.25%   
Talaris Therapeutics shows a total of 42.81 Million outstanding shares. The majority of Talaris Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Talaris Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Talaris Therapeutics. Please pay attention to any change in the institutional holdings of Talaris Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Talaris Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Talaris Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Talaris Stock Ownership Analysis

About 78.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.28. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Talaris Therapeutics recorded a loss per share of 1.97. The entity last dividend was issued on the 19th of October 2023. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people. To find out more about Talaris Therapeutics contact JD LLB at 502 398 9250 or learn more at https://talaristx.com.

Talaris Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Talaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Talaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Talaris Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Talaris Therapeutics Outstanding Bonds

Talaris Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Talaris Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Talaris bonds can be classified according to their maturity, which is the date when Talaris Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account